XTalks

MAY 2, 2024

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. Since January, the FDA has already signed off on more than a dozen novel drugs. The agency is reviewing applications for several highly anticipated drugs for approval in 2024.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

Drug Discovery World

NOVEMBER 15, 2022

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

Drug Discovery World

SEPTEMBER 25, 2023

The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and will evaluate the investigational vaccine for safety and its ability to elicit an immune response. “An If no safety concerns are identified, enrolment will begin in the higher dose (180 mcg per vaccination) group.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

NOVEMBER 30, 2023

New FDA-Approved Treatments For HIV HIV treatment involves the administration of combined antiretroviral therapy (ART) to effectively suppress the viral load, maintain or enhance immune function and reduce the risk of opportunistic infections and cancers commonly associated with HIV. percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

MARCH 23, 2023

The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID) and led by Mark M Davis, Director of the Stanford Institute for Immunity, Transplantation and Infection and a professor of microbiology and immunology at Stanford University School of Medicine in California.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Drug Discovery World

JANUARY 22, 2024

Sponsored by Integra Biosciences and Hamamatsu Corporation, it will explore technologies being used for drug discovery and how they get from lab to patient. Simon Bushell, SVP of Molecular Discovery at Entact Bio, will present: ‘Proximity-inducing drugs: Using technological innovation to build the next generation of medicine’.

Engineer 59

Engineer Immune Response Drugs Vaccination 59

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. © 2020 HealthDay. All rights reserved. Posted: December 2020.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

Scienmag

MARCH 3, 2021

Results could lead to better drugs used to fight inflammation At the beginning of an immune response, a molecule known to mobilize immune cells into the bloodstream, where they home in on infection sites, rapidly shifts position, a new study shows.

Immune Response 57

Immune Response Drugs Research Dermatology 57

pharmaphorum

JULY 12, 2022

Since then, outbreaks have occurred almost every year around the world, mainly in India and Bangladesh, and there is no approved vaccine or drug treatment to protect humans or animals at risk. “The need for a preventive Nipah virus vaccine is significant,” he added. .

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 17, 2021

Food and Drug Administration (FDA) are starting to pick up. The drug is being developed for several indications, but the NDA is for lupus nephritis (LN), a serious inflammation of the kidneys the result of systemic lupus erythematosus (SLE). Sarah Silbiger/Getty Images. After a start-of-the-year lull, activities at the U.S.

Manufacturing 52

Manufacturing Immune Response Allergies Drugs 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

OCTOBER 26, 2020

The National Institute of Allergy and Infectious Diseases (NIAID), the study sponsor, could not verify the safety issue, but their analysis also indicated there was little likelihood the antibody would help the hospitalized patients. The approval marks the first drug approved by the U.S. The drug is an orally active caspase inhibitor.

Antibody 52

Antibody Vaccination Vaccine Manufacturing 52

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The new research provides a scientific rationale to advance clinical studies of the drug combination in patients with AML. billion in total for three drugs.

Research 52

Research Protein Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2021

BTK is an intracellular signaling molecule involved in innate and adaptive immune responses involved in certain immune-mediated diseases. Allergy, 75: 100-119. By inhibiting BTK, rilzabrutinib has the potential to target the underlying disease pathogenesis. Arthritis Rheumatol. 2020 Apr 9;72(9):1435–46. doi: 10.1002/art.41275.

Trials 52

Trials Immune Response Allergies Clinical Trials 52

pharmaphorum

AUGUST 13, 2020

Bourla made Pfizer’s manufacturing capabilities available to small biotech concerns and is in talks to make large quantities of other companies’ COVID-19 drug candidates. AstraZeneca has joined forces with GSK and Sanofi to play a socially responsible role in the search for a vaccine and its rapid production.

Branding 112

Branding Vaccination Vaccine Filler 112

Bioengineer

JULY 15, 2021

But some patients develop resistance to current immunotherapies and others have cancers characterized by immunologically “cold” tumors, which evade or suppress the patient’s immune response against his or her cancer. Food & Drug Administration to begin testing this agent in human clinical trials.

Medicine 52

Medicine Clinical Trials Clinical Trials Scientist 52

Drug Discovery World

JANUARY 20, 2023

Janssen Vaccines & Prevention sponsored the Mosaico study with funding support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The post Experimental HIV vaccine safe but ineffective appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Immune Response Clinical Trials 52

Drug Discovery World

FEBRUARY 1, 2023

An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial. The post Chimpanzee adenovirus vaccine protects against Marburg virus appeared first on Drug Discovery World (DDW). Credit: NIAID.

Vaccination 52

Vaccination Vaccine Immune Response Clinical Trials 52

Drug Discovery World

FEBRUARY 3, 2023

One of these candidates is VSV-SUDV, developed and tested by scientists at NIH’s National Institute of Allergy and Infectious Diseases in Hamilton, Montana. The fact that four control animals got sick demonstrates that pre-existing immunity to EBOV and VSV-EBOV has limited effect on protection from SUDV.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

Pfizer

JULY 26, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. IMPORTANT SAFETY INFORMATION . has a fever.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Drug Discovery World

AUGUST 1, 2023

The NIH states: “This natural mechanism for sequence-specific gene silencing promises to revolutionise experimental biology and may have important practical applications in functional genomics, therapeutic intervention, agriculture and other areas.” There are many examples of ways in which RNAi is impacting drug discovery.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

The Pharma Data

APRIL 28, 2021

About Rilzabrutinib Rilzabrutinib is an oral, reversible covalent, Bruton’s tyrosine kinase (BTK) inhibitor being investigated for the treatment of immune mediated diseases. BTK is involved in innate and adaptive immune responses and is a signaling molecule in immune mediated diseases.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. 1) The Prescription Drug User Fee Act goal date for a decision by the FDA is during the first quarter of 2022. US Food and Drug Administration. Ann Allergy Asthma Immunol.

Allergies 52

Allergies Trials In-Vivo Medicine 52

XTalks

AUGUST 16, 2021

The US Food and Drug Administration (FDA) has amended its emergency use authorizations (EUA) for both the Pfizer and Moderna COVID-19 vaccines to incorporate a third dose for immunocompromised individuals. Related: CDC Backs J&J COVID-19 Shot Amid GBS and Delta Variant Concerns.

Vaccination 104

Vaccination Vaccine Antibody Immune Response 104

Pfizer

JULY 19, 2022

The companies’ previously announced safety, tolerability and immunogenicity data from a Phase 2/3 trial that found a 30 µg booster dose of the Omicron-adapted bivalent vaccine candidate elicited a superior immune response against Omicron BA.1 is immunocompromised or are on a medicine that affects the immune system. has a fever.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Pfizer

JULY 8, 2022

Following a third dose in this age group , the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo. Food and Drug Administration (FDA) which granted emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine as a three 3-µg dose series in this age group on June 17.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

The Pharma Data

DECEMBER 31, 2020

Food and Drug Administration (FDA) issued Emergency Use Authorization for two COVID-19 vaccines: Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. Professional.

Vaccination 52

Vaccination Vaccine FDA Approval Hormones 52

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration Breakthrough Therapy Designation granted to tezepelumab in Sept. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Food and Drug Administration for the products. 10 World Allergy Organization (WAO).

Trials 52

Trials Production Sales Manufacturing 52

Pfizer

JULY 8, 2022

Food and Drug Administration (FDA) approved the companies’ supplemental Biologics License Application (sBLA) for their COVID-19 vaccine, known as COMIRNATY® (COVID-19 Vaccine, mRNA), to include individuals 12 through 15 years of age. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

The Pharma Data

DECEMBER 21, 2020

In September 2018 , the US Food and Drug Administration granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.

Trials 40

Trials Production Sales Manufacturing 40

The Pharma Data

FEBRUARY 8, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June and will be listed on the NRDL (National Reimbursement Drug List) as of March 2021. Allergy Cough & Cold. to €238 million, reflecting growth in the Allergy (Allegra ® and Xyzal ® ) and Digestives categories. Consumer Healthcare.

Sales 52

Sales Vaccination Vaccine Production 52

The Pharma Data

FEBRUARY 4, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June and will be listed on the NRDL (National Reimbursement Drug List) as of March 2021. Allergy Cough & Cold. to €238 million, reflecting growth in the Allergy (Allegra ® and Xyzal ® ) and Digestives categories. Consumer Healthcare.

Sales 52

Sales Vaccination Vaccine Production 52

The Pharma Data

APRIL 27, 2021

Dupixent ® was approved in China for the treatment of adults with moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. to €283 million, reflecting growth of Digestive and Mental Wellness categories as well as Allergy partially offset by the decline of the Pain category.

Sales 52

Sales Vaccination Vaccine Medicine 52

pharmaphorum

JULY 26, 2022

With the option to medicate with pre-exposure prophylaxis (PrEP), the chance of transmitting HIV from sex or drug use through injection has also been greatly reduced. Leronlimab blocks HIV from entering immune cells due to a surface protein called CCR5.

Gene Therapy 140

Gene Therapy Protein Vaccination Vaccine 140

Pharmaceutical Technology

APRIL 20, 2023

Following a tumultuous development cycle, DBV Technologies will now have to conduct an additional safety study of its peanut allergy Viaskin patch in toddlers ages 1–3 years, based on written correspondence from the US Food and Drug Administration (FDA). However, the French company will not be required to run a further efficacy study.

Allergies 130

Allergies Trials Immune Response Licensing 130

Pfizer

NOVEMBER 2, 2022

The influenza virus is subject to constant mutations to evade the host immune response, causing a seasonal variation in circulating strains. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. are immunocompromised or are on a medicine that affects the immune system.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85